hERG Channel Assay
Cardiac safety assessment stands as an unnegotiable pillar in modern drug discovery, and hERG Channel Assay represents the gold-standard prerequisite for de-risking lead candidates. The human Ether-à-go-go-Related Gene (hERG) encodes the rapidly activating delayed rectifier potassium channel (IKr), whose inhibition is the primary cause of drug-induced QT interval prolongation—a life-threatening condition linked to Torsades de Pointes and sudden cardiac arrest. Regulatory guidelines (ICH S7B, E14, FDA, NMPA) mandate rigorous hERG profiling for all new chemical entities before clinical trials. By identifying early-stage hERG liability, PharmaAnalytica empowers clients to make critical go/no-go decisions, drastically reducing costly late-stage attrition and ensuring compliance with global GLP safety standards, thus safeguarding both patient safety and developmental momentum.
PharmaAnalytica delivers a tiered hERG testing strategy tailored to lead optimization workflows, combining high-throughput screening with definitive electrophysiological validation.
- Fluorescent Thallium Flux Assay: Serves as the primary screening tool, utilizing fluorescence-based detection to indirectly measure channel activity via ion flux, enabling rapid, cost-effective batch screening of large lead libraries.
- Automated Patch-Clamp Electrophysiology: The gold-standard method that directly records hERG potassium currents with GΩ-seal quality, providing precise IC50 values and full current-voltage (IV) characterization.
PharmaAnalytica's Technology Platform
Au-Mate 96 A4 Liquid Handling Workstation
This 96-channel automated system executes precise compound serial dilution, gradient dosing, and 96/384-well plate preparation with unmatched consistency. Featuring a 4-position motorized platform and intuitive touchscreen control, it eliminates manual pipetting errors, accelerates high-throughput lead screening, and preserves assay integrity for large-scale hERG liability testing.
Feyond-A500 Multifunctional Fluorescence Microplate Reader
As our advanced detection workhorse, this top-tier model integrates absorbance, fluorescence, luminescence, time-resolved fluorescence, and fluorescence polarization detection modes. It delivers ultra-high sensitivity (detection limit down to 1pM) and a broad wavelength range, enabling precise quantification of ion flux signals in the Thallium Flux Assay, ensuring robust and reliable screening of lead compounds.
TPC-200 Patch-Clamp System
The TPC-200 is a low-noise, high-performance patch-clamp amplifier for hERG channel assays. It enables whole-cell voltage-clamp recordings with precise automatic capacitance/series resistance compensation, 16-bit 200 kHz data acquisition, and 8-pole Bessel filtering. Delivering pA-level current resolution and stable voltage control, it reliably measures hERG tail-current inhibition and IC₅₀ for cardiac safety pharmacology.
PharmaAnalytica's hERG Channel Assay Service
Expert Scientific Team
Our assay is developed and run by a dedicated team of electrophysiologists and pharmacologists with deep expertise in ion channel safety pharmacology, ensuring method optimization and flawless execution.
Customized Service
We offer flexible study designs, from single-point screening to full dose-response and kinetic analysis, tailored to your lead compound's specific stage and needs.
Advanced Data Analysis
We provide in-depth, customized data analysis including IC50 calculation, IV curve fitting, and mechanistic interpretation, delivering clear, actionable insights beyond raw numbers.
Integrated Safety Package
Seamlessly combine hERG testing with our cytotoxicity and other safety assays for a holistic preclinical profiling solution.
Partner with PharmaAnalytica to transform your lead discovery with confident, compliant, and cutting-edge cardiac safety assessment.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
